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Abstract
Retinitis pigmentosa (RP) is a hereditary disease that leads to the progressive degeneration of retinal photoreceptor cells
and to blindness. It is caused by mutations in several distinct genes, including the ciliary gene FAM161A, which is associated
with a recessive form of this disorder. Recent investigations have revealed that defects in FAM161A represent a rather
prevalent cause of hereditary blindness in Israel and the Palestinian territories, whereas they seem to be rarely present
within patients from Germany. Genetic or clinical data are currently not available for other countries. In this work, we
screened a cohort of patients with recessive RP from North America to determine the frequency of FAM161A mutations in
this ethnically-mixed population and to assess the phenotype of positive cases. Out of 273 unrelated patients, only 3
subjects had defects in FAM161A. A fourth positive patient, the sister of one of these index cases, was also identified
following pedigree analysis. They were all homozygous for the p.T452Sfx3 mutation, which was previously reported as a
founder DNA variant in the Israeli and Palestinian populations. Analysis of cultured lymphoblasts from patients revealed that
mutant FAM161A transcripts were actively degraded by nonsense-mediated mRNA decay. Electroretinographic testing
showed 30 Hz cone flicker responses in the range of 0.10 to 0.60 microvolts in all cases at their first visit (age 12 to 23) (lower
norm = 50 mV) and of 0.06 to 0.32 microvolts at their most recent examination (age 27 to 43), revealing an early-onset of
this progressive disease. Our data indicate that mutations in FAM161A are responsible for 1% of recessive RP cases in North
America, similar to the prevalence detected in Germany and unlike the data from Israel and the Palestinian territories. We
also show that, at the molecular level, the disease is likely caused by FAM161A protein deficiency.
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Introduction
Retinitis pigmentosa (RP) is a group of hereditary degenerative
diseases of the retina displaying a significant phenotypic and
genotypic variability and characterized by the progressive decrease
of rod and cone photoreceptor function. Patients typically report
loss of night vision during adolescence, loss of mid and far
peripheral field in young adulthood, and loss of central vision in
later life. Characteristic clinical features are elevated final dark
adaptation thresholds and reduced and delayed full-field electro-
retinogram (ERG) signals, measuring the electrical response of the
retina to flashes of light [1]. At present, according to the RetNet
database (https://sph.uth.edu/retnet/), over 60 genes have been
associated with nonsyndromic RP, which account for 50-60% of
patients with this condition [2,3].
Mutations in FAM161A have been found to represent the cause
of RP28-associated autosomal recessive RP (arRP) in the initial
Indian family in which the RP28 locus was mapped [4], as well as
in a cohort of German patients [5]. Frequent nonsense mutations
in FAM161A were also identified in patients from Israel and the
Palestinian territories [6]. FAM161A is evolutionarily conserved in
vertebrates [5,6] and, despite having multiple splicing variants,
only two of them produce stable mRNA transcripts. The main
splicing variant contains 6 exons and encodes a protein of 76 kDa,
while the second variant contains a supplementary 168 bp in-
frame exon between exons 3 and 4 [5,6]. The protein is mainly
expressed in the retina and in the testis and localizes in
photoreceptor cells during mouse retinal development [5,6]. More
specifically, FAM161A localizes at the base of the photoreceptor
connecting cilium and at the ciliary basal body [7,8]. Patients with
FAM161A mutations have been reported to have symptoms
ranging from an atypically late-onset form of RP, detected in the
German cohort mentioned above, to an early-onset manifestation
of the disease, as observed in Israeli and Palestinian individuals
[5,6]. Unexpectedly, despite these clinical differences, all patients
who have been ascertained so far carry the same class of
mutations, leading to premature stops of the open reading frame.
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FAM161A Mutation in North American arRP Patients
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e92479Here we report results of our mutational screening of FAM161A
in a cohort of patients with autosomal recessive RP from North
America, with the aim of assessing the mutation spectrum in this
population and investigating any possible genotype/phenotype
correlation.
Methods
Patients and Controls
This research was carried out in accordance with the tenets of
the Declaration of Helsinki and was approved by the Institutional
Review Boards of the University of Lausanne and of Harvard
Medical School and the Massachusetts Eye and Ear, where the
blood was collected and the patients were followed. Written
informed consent was obtained from patients who participated in
this study or from their legal guardians before they donated 10-
30 ml of their blood for research.
All patients were evaluated with respect to best-corrected
Snellen acuities, kinetic visual fields on the Goldmann perimeter
with a V-4e white test light, final dark adaptation thresholds with
an 11u white test light in a Goldmann-Weekers dark adaptometer,
and full-field cone ERGs in response to 30 Hz white flicker
obtained with narrow bandpass filtering and computer averaging,
as described previously [9]. After dilation, all had a slit-lamp
examination, fundus evaluation with direct and indirect ophthal-
moscopy, and fundus photography.
DNA from peripheral blood leukocytes was extracted from 273
unrelated patients with arRP from North America, representing
an ethnically-mixed population. Controls included 95 individuals
with no history of retinal degeneration and 80 subjects with
normal ERGs. In addition, DNA samples from 95 ethnically-
matched healthy individuals were purchased from the Coriell
Institute Repository. Initial screening of FAM161A sequence was
performed on whole-genome amplified DNA (REPLI-g Mini Kit,
Qiagen). All samples that were found to be positive for DNA
changes were then PCR-amplified and sequenced a second time,
starting from original DNA.
Mutation Screening
Primer pairs for individual exons and relevant intron bound-
aries were designed using the CLCbio Genomics Workbench
(Table S1). Amplifications by PCR were performed in 25 ml
reactions containing 20 ng genomic DNA, 16 GoTaq buffer,
1.2 mM MgCl2, 0.1 mM dNTPs, 0.4 mM of each primer, and
0.01 U/ml of GoTaq polymerase (Promega). Amplification condi-
tions were: an initial step at 95uC for 2 minutes, 35 cycles of
denaturation at 94uC for 30 seconds, annealing according to
primers’ melting temperature for 30 seconds, and extension at
72uC for 1 minute. Before the end of the reaction, a final extension
step at 72uC for 5 minutes was performed.
Sequencing reactions were carried out by Sanger sequencing,
after purification of PCR products (ExoSAP-IT, USB), by using
1 ml of 3.3 mM sequencing primer (Table S2) and 0.5 ml of BigDye
Terminator v1.1 (Applied Biosystems). The products of these
sequencing reactions were run on an ABI-3130XLS sequencer
(Applied Biosystems).
Cell Culture and Drug Treatment
The Epstein-Barr virus immortalized lymphoblastoid cell lines
that were used in this study were derived from two affected
patients (003-161 and her sibling 012-001), and were cultured as
previously described [10]. Normal control cell lines were
purchased from the Coriell Cell Repository. RNA extraction,
cDNA synthesis, and treatment of cells with cycloheximide was
performed as previously reported [11].
FAM161A primers for cDNA amplification were 59-ggaagaaac-
gaaaagaatgg-39 and 59–ttctcgttggtattctctcatcc-39, yielding a
1,115 bp product. 18S ribosomal RNA was used as a housekeep-
ing gene for this analysis, and primers for its cDNA amplification
Figure 2. Schematic representation of alternative splicing
events of FAM161A transcripts. Boxes represent exons, while lines
represent splicing events. Coding regions are in black, noncoding
regions are white. The canonical forms of FAM161A mRNA are
presented in the top panel, as reference. The bottom two panels show
newly-discovered splicing isoforms with an alternative 59UTR in intron 1
(1a).
doi:10.1371/journal.pone.0092479.g002
Figure 1. Mutation c.1355_6delCA (p.T452SfsX3) produces
transcripts with a premature stop codon that are targets for
NMD degradation. The image shows an agarose gel on which six RT-
PCR products were run: two from patients 003-161 and 102-001,
respectively, one from a control cell line (CTR), and one from the same
control cell line, following a cDNA synthesis reaction performed without
the addition of the reverse transcriptase enzyme (RT-). Presence of
cycloheximide in cell cultures is indicated with "+", its absence with "2".
M, DNA molecular size marker; 18S, RT-PCR loading control (18S rRNA);
1000 bp and 250 bp, bands of the marker corresponding to these
specific sizes, respectively.
doi:10.1371/journal.pone.0092479.g001
FAM161A Mutation in North American arRP Patients
PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e92479were 59-cggctaccacatccaaggaa-39 and 59–gctggaattaccgcggct-39
(resulting in a 187 bp product).
RNA Ligase Mediated Rapid Amplification of cDNA Ends
(RLM-RACE)
To perform RLM-RACE we used the FirstChoice RLM-RACE
kit (Invitrogen), following the manufacturer’s instruction. One
microgram of total RNA from human retina (Clontech) was used
to perform 39UTR RLM-RACE, and ten micrograms of total
RNA from human retina (Clontech) and from retinoblastoma cell
line Y79 were used to perform 59UTR RLM-RACE.
Results
Molecular Genetic Analysis
We screened FAM161A in 273 unrelated patients with arRP
from North America, and in 270 ethnically matched healthy
individuals. In three of these patients we identified the null
mutation p.Thr452SerfsX3, which was previously reported as a
founder mutation in an Israeli Jewish population [6]. Following
the pedigree analysis of these three index patients, we identified an
additional affected family member (012-001, sister of 003-161),
who was also found to be positive for the same mutation. All four
patients were homozygous for p.Thr452SerfsX3 (Table 1). All
controls were negative for this DNA change.
p.Thr452SerfsX3 is predicted to produce a transcript that could
be a target for nonsense mediated mRNA decay (NMD) and
therefore result in no protein product [12]. In order to test this
hypothesis, we analyzed lymphoblastoid cell lines derived from the
two siblings carrying this change (003-161 and 012-001). RT-
PCRs of FAM161A mRNA from both cell lines, cultured in
standard conditions, yielded a rather poor amplification product,
indicative of mRNA degradation. Conversely, supplementation
with the chemical NMD inhibitor cycloheximide reversed this
phenomenon and allowed good amplification, confirming that
p.Thr452SerfsX3 results in a null allele (Figure 1).
In our cohort we also found a few other rare variants, likely
having no pathological relevance (Table 1). Variant p.Q385E
(rs139266382; Minor Allele Frequency, or MAF,0.01) was
previously identified as a heterozygous change in arRP patients
and in healthy controls with a frequency of 2/400 alleles [5]. In
our screening, we identified it in one patient and in 2 individuals
from our control cohort. Variant p.H464R (rs201315315,
MAF,0.01) was found as a heterozygous change in one arRP
patient and in no healthy controls. Variant p.D371E was neither
annotated in the dbSNP database [13] nor was found in the
control cohort, but was found in a heterozygous state in one
patient. However, it involved an amino acid residue that is not
conserved across species and was predicted to result in a benign
change by in silico analyses.
Variant p.L378R was previously identified in the heterozygous
state in a cohort of German patients with recessive or isolated
forms of RP and classified as a rare variant with uncertain
pathogenicity [5]. It involves a highly conserved residue and is
predicted to be deleterious by 3 out of 4 prediction programs
(Polyphen, SIFT, MutPred, and PMut) [14–17]. Recently, it has
been annotated in the dbSNP database (build 135/138,
rs187695569), with a MAF of 0.003. We identified it in a
heterozygous state in 5 out of 273 arRP patients and in 2 healthy
individuals from the Coriell control cohort.
To test the hypothesis that heterozygous changes detected in
our cohort of patients could in fact represent unrecognized
mutations, we ascertained whether there were other non-
annotated FAM161A exons in the human retina. We therefore
performed 59 and 39 RLM-RACE PCR using pooled retinal RNA
from different donors, and identified two additional transcripts
with an alternative 59UTR in intron 1, whose sequence
corresponds to the annotated exon 2 of FAM161A-003 isoform.
Figure 3. Fundus photographs from patient 121–385 (male, 43 years old). The patient shows the representative phenotype of this mutation
with waxy pallor of the optic disc, retinal arteriolar attenuation, granularity of the macula and intra retinal pigment around the midperiphery in a
bone spicule or clumped configuration.
doi:10.1371/journal.pone.0092479.g003
FAM161A Mutation in North American arRP Patients
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levels compared to the major isoforms, the translation-initiation
codon may lie in exon 2 (Figure 2) [6]. Interestingly, one of them
completely skipped the highly-conserved exon 3, where most
FAM161A mutations have been so far reported. Furthermore,
despite the absence of exon 1 and the skipping of exon 3, in both
newly-discovered isoforms the original FAM161A open reading
frame appeared to be preserved, possibly leading to translation of
these transcripts. We therefore screened this alternative 59UTR
sequence in the patients, but we did not find any likely
pathological variant.
Clinical Evaluation of the Patients
Clinical evaluation at initial visits showed preserved visual
acuity, constricted visual fields, and reduced but detectable 30 Hz
cone ERGs in all 4 patients with known pathogenic mutations
(Table 2). All had bone spicule pigment in the periphery (Figure 3).
At follow up, 10 to 20 years later, each patient showed preserved
acuity in at least one eye and cone ERGs comparable in amplitude
to those at their initial visits. Because of a possible floor effect [9],
further degeneration was difficult to quantify in these patients due
to their small initial ERGs amplitudes.
Discussion
Mutations in FAM161A were recently reported to cause
autosomal recessive retinitis pigmentosa by two independent
studies [5,6]. However, despite mutations corresponded in all
cases to DNA changes that lead to the premature termination of
the reading frame, both prevalence and clinical severity of
FAM161A-linked disease seem to be population-specific and/or
dependent on the presence of other modifier genes. In Germany,
this gene is mutated with a prevalence that is comparable to that of
most arRP genes (1–2%) and is found in patients with a
remarkably late-onset of the disease [5]. In Israel and in the
Palestinian territories, FAM161A mutations account for about 12%
of recessive RP cases, who have symptoms and signs of disease
much earlier in their life [6].
Among 273 unrelated recessive patients screened in our study,
only 3 were positive for FAM161A mutations, and in particular for
p.T452Sfx3, indicating that this gene is rarely associated with RP
in North America. Interestingly, p.T452Sfx3 was previously
reported as a founder mutation in the Israeli and Palestinian
populations [6], and all but one of our patients reported Jewish
ancestry. Furthermore, from our study it emerged that a few
patients carried rare heterozygous variants that were absent or had
an allele frequency of less than 1% in the general population, and
that had an uncertain functional significance.
Patients with FAM161A mutations clinically showed early-onset
RP with relatively good acuity and very reduced cone ERGs.
Follow-up examinations 10–20 years after the initial visit showed
that all retained good acuity in at least one eye, 3 out of 4 showed
further loss of visual field, and 1 showed further decline in the
ERG. A floor effect may have occurred in those with less than or
equal to 0.34 mV at their initial visit that could simulate
stabilization or even improvement. Visual field areas to the V-4e
white test light were all below normal. The phenotype was that of
typical retinitis pigmentosa in all 4 cases. The long-term course of
arRP associated with FAM161A mutations remains to be defined.
Finally, our analysis of FAM161A transcripts revealed that
p.T452Sfx3 probably results in a functionally null allele, in view of
the premature termination codon introduced by the mutation.
Since all other pathogenic changes detected so far belong to this
same class of mutations, it is likely that the disease is caused by
deficiency of FAM161A protein, making the FAM161A gene a
good candidate for gene replacement studies.
Supporting Information
Table S1 Primers for polymerase chain reaction am-
plification of FAM161A exons.
(PDF)
Table S2 Primers for Sanger sequencing of FAM161A
exons.
(PDF)
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